Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP1 | Q9NZ08 | 4/20 | 0.51 |
| ▸ | ERAP2 | Q6P179 | 3/20 | 0.51 |
| ▸ | IL1RN | P18510 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CTSC | P53634 | 1/20 | 0.47 |
| ▸ | ANPEP | P15144 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28107772 | 0.89 | ERAP1 (0.52) | ERAP1ERAP2IL1RNTSHRANPEP | |
| SCHEMBL1285521 | 0.88 | ERAP1 (0.50) | ERAP1ERAP2IL1RNTSHRANPEP | |
| SCHEMBL30136523 | 0.87 | ERAP1 (0.51) | ERAP1ERAP2IL1RNTSHRANPEP | |
| Water SCHEMBL27496794 | 0.86 | ERAP1 (0.49) | ERAP1ERAP2IL1RNTSHRCTSC | |
| SCHEMBL585398 | 0.85 | CYP1A2 (0.59) | ERAP1ERAP2CA2TSHRANPEP | |
| SCHEMBL10436216 | 0.85 | CA1 (0.53) | ERAP1ERAP2IL1RNCA1CA2 | |
| Hydrochloric Acid SCHEMBL28284494 | 0.84 | CYP1A2 (0.57) | ERAP1ERAP2CA2TSHRANPEP | |
| SCHEMBL16938789 | 0.84 | ERAP1 (0.49) | ERAP1ERAP2IL1RNTSHRANPEP | |
| SCHEMBL27417767 | 0.84 | CYP1A2 (0.57) | ERAP1ERAP2IL1RNANPEPCYP1A2 | |
| SCHEMBL4183117 | 0.83 | CNR2 (0.49) | ERAP1ERAP2IL1RNCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12351580-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-20240067649-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2024-02-29 | — | — | US | disclosed |
| US-11827632-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2023-11-28 | — | — | US | disclosed |
| US-20220289736-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2022-09-15 | — | — | US | disclosed |
| CN-107473980-A | A kind of application of amides compound in bacterial community sensing activity inhibitor is prepared | 浙江工业大学 | 2017-12-15 | — | — | CN | disclosed |
| CN-107108467-A | cell necrosis inhibitor | 北京生命科学研究所 | 2017-08-29 | — | — | CN | disclosed |
| EP-0975600-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | Akzo Nobel N.V. (NL) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998047876-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | AKZO NOBEL N.V. (NL) | 1998-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827632-B2 | NLRP3 modulators | NLRP3, NLRP1, NOD1 | ERAP1 2308/4885ERAP2 2513/4885IL1RN 18/4885 |
| US-20220289736-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, NOD1 | ERAP1 2308/4885ERAP2 2513/4885IL1RN 18/4885 |
| US-12351580-B2 | NLRP3 modulators | NLRP3, NLRP1, NOD1 | ERAP1 2308/4885ERAP2 2513/4885IL1RN 18/4885 |
| US-20240067649-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, NOD1 | ERAP1 2308/4885ERAP2 2513/4885IL1RN 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.